Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

Affiliations

¹ Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
² Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
³ Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, 169610, Singapore.
⁴ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore.
⁵ Division of Surgical Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
⁶ Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
⁷ Department of Urology, Singapore General Hospital, Singapore, 169608, Singapore.
⁸ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
⁹ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.
¹⁰ Department of Colorectal Surgery, Singapore General Hospital, Singapore, 169608, Singapore.
¹¹ Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore. mcbzengq@imcb.a-star.edu.sg.
¹² Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore. mcbzengq@imcb.a-star.edu.sg.

^# Contributed equally.

Published Erratum

Min Thura et al. Nat Commun. 2021.

. 2021 Nov 2;12(1):6431.

doi: 10.1038/s41467-021-26548-6.

¹ Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.
² Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
³ Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, 169610, Singapore.
⁴ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore.
⁵ Division of Surgical Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.
⁶ Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
⁷ Department of Urology, Singapore General Hospital, Singapore, 169608, Singapore.
⁸ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
⁹ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.
¹⁰ Department of Colorectal Surgery, Singapore General Hospital, Singapore, 169608, Singapore.
¹¹ Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore. mcbzengq@imcb.a-star.edu.sg.
¹² Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119260, Singapore. mcbzengq@imcb.a-star.edu.sg.

^# Contributed equally.

No abstract available

Erratum for

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. Thura M, et al. Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x. Nat Commun. 2019. PMID: 31171773 Free PMC article.